Dashboard
Manage Tickers

TVTXTravere Therapeutics, Inc.


$ 14.40 $ -0.04 (-0.28 %)    

Tuesday, 17-Sep-2024 15:49:43 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 472.87 $ -3.10 (-0.65 %)
DIA $ 416.82 $ -1.17 (-0.28 %)
SPY $ 562.38 $ -2.75 (-0.49 %)
TLT $ 100.90 $ -0.49 (-0.48 %)
GLD $ 237.32 $ -0.66 (-0.28 %)
$ na
$ 14.44
$ 14.38 x 100
$ 14.39 x 250
$ 14.01 - $ 14.76
$ 5.12 - $ 14.72
3,738,987
na
1.09B
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jp-morgan-maintains-overweight-on-travere-therapeutics-raises-price-target-to-23
JP Morgan Maintains Overweight on Travere ...
09/13/2024 19:26:43

JP Morgan analyst Anupam Rama maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

canaccord-genuity-maintains-buy-on-travere-therapeutics-raises-price-target-to-23
Canaccord Genuity Maintains Buy on Travere...
09/10/2024 15:05:17

Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target fr...

Core News & Articles
This United States Steel Analyst Turns Bul...
09/09/2024 13:17:23

guggenheim-upgrades-travere-therapeutics-to-buy-announces-25-price-target
Guggenheim Upgrades Travere Therapeutics t...
09/09/2024 11:01:52

Guggenheim analyst Vamil Divan upgrades Travere Therapeutics (NASDAQ:TVTX) from Neutral to Buy and announces $25 price target.

analyst-ratings-for-travere-therapeutics
Analyst Ratings For Travere Therapeutics
09/06/2024 21:00:37

citigroup-maintains-buy-on-travere-therapeutics-raises-price-target-to-23
Citigroup Maintains Buy on Travere Therape...
09/06/2024 18:47:09

Citigroup analyst Carly Kenselaar maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $...

quanex-building-products-posts-better-than-expected-results-joins-zumiez-guidewire-software-smartsheet-and-other-big-stocks-moving-higher-on-friday
Quanex Building Products Posts Better-Than...
09/06/2024 14:11:39

b-of-a-securities-maintains-buy-on-travere-therapeutics-raises-price-target-to-19
B of A Securities Maintains Buy on Travere...
09/06/2024 13:03:55

B of A Securities analyst Greg Harrison maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

nio-to-rally-around-65-here-are-10-top-analyst-forecasts-for-friday
NIO To Rally Around 65%? Here Are 10 Top A...
09/06/2024 12:16:38

hc-wainwright--co-maintains-buy-on-travere-therapeutics-raises-price-target-to-23
HC Wainwright & Co. Maintains Buy on Trave...
09/06/2024 11:22:13

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

trading-halt-halt-status-updated-at-70500-pm-et-quotation-resumption-news-and-resumption-times
Trading Halt: Halt status updated at 7:05:...
09/05/2024 23:05:07

travere-says-fda-has-granted-full-approval-to-filspari-sparsentan-to-slow-kidney-function-decline-in-adults-with-primary-igan-who-are-at-risk-of-disease-progression
Travere Says FDA Has Granted Full Approval...
09/05/2024 21:36:01

FILSPARI was granted accelerated approval in February 2023 based on the surrogate marker of proteinuria. Full approval is based...

trading-halt-halted-at-43447-pm-et---trading-halt-halt-news-pending
Trading Halt: Halted at 4:34:47 p.m. ET - ...
09/05/2024 20:34:51

jp-morgan-maintains-overweight-on-travere-therapeutics-raises-price-target-to-20
JP Morgan Maintains Overweight on Travere ...
08/13/2024 12:29:09

JP Morgan analyst Anupam Rama maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

hc-wainwright--co-maintains-buy-on-travere-therapeutics-raises-price-target-to-20
HC Wainwright & Co. Maintains Buy on Trave...
08/05/2024 19:24:21

HC Wainwright & Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target ...

barclays-maintains-overweight-on-travere-therapeutics-raises-price-target-to-14
Barclays Maintains Overweight on Travere T...
08/02/2024 14:07:53

Barclays analyst Carter Gould maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and raises the price target fro...

expert-ratings-for-travere-therapeutics
Expert Ratings For Travere Therapeutics
08/02/2024 14:00:23

piper-sandler-maintains-neutral-on-travere-therapeutics-raises-price-target-to-12
Piper Sandler Maintains Neutral on Travere...
08/02/2024 13:55:24

Piper Sandler analyst Allison Bratzel maintains Travere Therapeutics (NASDAQ:TVTX) with a Neutral and raises the price targe...

wedbush-maintains-outperform-on-travere-therapeutics-raises-price-target-to-16
Wedbush Maintains Outperform on Travere Th...
08/02/2024 13:08:14

Wedbush analyst Laura Chico maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from ...

travere-therapeutics-files-mixed-securities-shelf-size-not-disclosed
Travere Therapeutics Files Mixed Securitie...
08/01/2024 21:38:37

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION